xT CDx with HLA-LOH assay

DIAGNOSTIC_TEST2 trials

Sponsors

A2 Biotherapeutics Inc.

Conditions

CRCCancerColon CancerColorectal AdenocarcinomaColorectal CancerHNSCCHead and Neck Squamous Cell CancerKidney Cancer

Phase 1

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

RecruitingNCT06051695

A2 Biotherapeutics Inc.Cancer, Colon Cancer, Colorectal Adenocarcinoma +17

Start: 2024-04-03End: 2029-06-01Target: 474Updated: 2026-06-12

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

RecruitingNCT06682793

A2 Biotherapeutics Inc.Cancer, Colon Cancer, Colorectal Adenocarcinoma +14

Start: 2025-05-22End: 2030-03-31Target: 240Updated: 2025-09-09

Related Papers

Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH).

Journal of Clinical Oncology2026-05-28

A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study.

Journal of Clinical Oncology2026-05-28

Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial.

Journal of Clinical Oncology2025-05-282 citations

EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).

Journal of Clinical Oncology2025-05-282 citations

Abstract CT186: EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity

Cancer Research2025-04-25

Correlation of mesothelin (MSLN) expression measured by RNA sequencing (RNASeq) and immunohistochemistry (IHC) in MSLN-expressing tumors.

Journal of Clinical Oncology2025-01-27

EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH).

Journal of Clinical Oncology2025-01-27

EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).

Journal of Clinical Oncology2024-06-015 citations